Preoperative neutrophil/lymphocyte ratio predicts overall survival and extravesical disease in patients undergoing radical cystectomy

Journal of Endourology

Volumn 27, Issue 8, 2013, Pages 1046-1050

  Krane, L Spencer ^a   Richards, Kyle A ^a   Kader, A Karim ^a   Davis, Ronald ^a   Balaji, K C ^a   Hemal, Ashok K ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; CREATININE; HEMOGLOBIN; SERUM ALBUMIN;

ADULT; AGED; ARTICLE; BLADDER DISEASE; BLOOD CELL COUNT; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CREATININE BLOOD LEVEL; CYSTECTOMY; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; HYPOALBUMINEMIA; LEUKOCYTE; LEUKOCYTOSIS; LYMPH NODE; LYMPH NODE DISSECTION; LYMPHOCYTE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MUSCLE INVASIVE BLADDER CANCER; NEUTROPHIL; NEUTROPHIL COUNT; OVERALL SURVIVAL; PELVIS LYMPH NODE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOSIS; TRANSITIONAL CELL CARCINOMA;

AGED; CYSTECTOMY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOCYTES; MALE; NEOPLASM INVASIVENESS; NEUTROPHILS; NORTH CAROLINA; PREOPERATIVE PERIOD; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 84882932025     PISSN: 08927790     EISSN: 1557900X     Source Type: Journal    
DOI: 10.1089/end.2012.0606     Document Type: Article

References (30)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Michaud DS. Chronic inflammation and bladder cancer. Urol Oncol 2007;25:260-268. (Pubitemid 46670749)
3. Rosin MP, Anwar WA, Ward AJ. Inflammation, chromosomal instability, and cancer: The schistosomiasis model. Cancer Res 1994;54(suppl 7):1929s-1933s. (Pubitemid 24132148)
4. Groah SL, Weitzenkamp DA, Lammertse DP, et al. Excess risk of bladder cancer in spinal cord injury: Evidence for an association between indwelling catheter use and bladder cancer. Arch Phys Med Rehabil 2002;83:346-351. (Pubitemid 34204816)
5. Castelao JE, Yuan JM, Gago-Dominguez M, et al. Nonsteroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 2000;82:1364-1369. (Pubitemid 30145360)
6. Jung MR, Park YK, Jeong O, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol 2011;104:504-510.
7. Gomez D, Farid S, Malik HZ, et al. Preoperative neutrophilto-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg 2008;32:1757-1762.
8. Tomita M, Shimizu T, Ayabe T, et al. Preoperative neutrophil to lymphocyte ratio as a prognostic predictor after curative resection for non-small cell lung cancer. Anticancer Res 2011;31:2995-2998.
9. Lee YY, Choi CH, Kim HJ, et al. Pretreatment neutrophil: Lymphocyte ratio as a prognostic factor in cervical carcinoma. Anticancer Res 2012;32:1555-1561.
10. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 2001;19:666-675. (Pubitemid 32120143)
11. Ghoneim MA, Abdel-Latif M, el-Mekresh M, et al. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol 2008;180:121-127.
12. Gondo T, Nakashima J, Ohno Y, et al. Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology 2012;79: 1085-1091.
13. Goldman L, Schafer AI, eds. Goldman's Cecil Medicine. Philadelphia: Elsevier/Saunders, 2012.
14. Madersbacher S, Hochreiter W, Burkhard F, et al. Radical cystectomy for bladder cancer today - a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003;21:690-696. (Pubitemid 46621904)
15. Gibbs J, Cull W, Henderson W, et al. Preoperative serum albumin level as a predictor of operative mortality and morbidity: Results from the National VA Surgical Risk Study. Arch Surg 1999;134:36-42. (Pubitemid 29047211)
16. Gregg JR, Cookson MS, Phillips S, et al. Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer. J Urol 2011;185:90-96.
17. Thrasher JB, Frazier HA, Robertson JE, et al. Clinical variables which serve as predictors of cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 1994;73:1708-1715. (Pubitemid 24085274)
18. Yurut-Caloglu V, Caloglu M, Kaplan M, et al. Pre-treatment hemoglobin levels are important for bladder carcinoma patients with extravesical extension undergoing definitive radiotherapy. Asian Pac J Cancer Prev 2009;10:1151-1157.
19. Joynson CP, Sundar S, Symonds P. Anaemia is associated with poor overall survival but not with inferior local control in patients with muscle invasive bladder carcinoma treated by radical external beam radiotherapy. A retrospective study. Clin Oncol (R Coll Radiol) 2006;18:728-734. (Pubitemid 44645408)
20. Bellmunt J, Choueiri TK, Fougeray R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinumcontaining regimens. J Clin Oncol 2010;28:1850-1855.
21. Daugherty SE, Pfeiffer RM, Sigurdson AJ, et al. Nonsteroidal antiinflammatory drugs and bladder cancer: A pooled analysis. Am J Epidemiol 2011;173:721-730.
22. Yoshida S, Saito K, Koga F, et al. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int 2008;101: 978-981. (Pubitemid 351422558)
23. Gakis G, Todenhö fer T, Renninger M, et al. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: The TNR-C score. BJU Int 2011;108:1800-1805.
24. Kitayama J, Yasuda K, Kawai K, et al. Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer. Radiat Oncol 2010;5:47.
25. Sato H, Tsubosa Y, Kawano T. Correlation between the pretherapeutic neutrophil to lymphocyte ratio and the pathologic response to neoadjuvant chemotherapy in patients with advanced esophageal cancer. World J Surg 2012; 36:617-622.
26. Stadler WM, Lerner SP, Groshen S, et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol 2011;29:3443-3449.
27. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-866. (Pubitemid 37025405)
28. David KA, Milowsky MI, Ritchey J, et al. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: A report from the National Cancer Data Base. J Urol 2007;178:451-454. (Pubitemid 47030482)
29. Raj GV, Karavadia S, Schlomer B, et al. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer 2011;117:276-281.
30. Quinn J, Kramer N, McDermott D. Validation of the Social Security Death Index (SSDI): An important readily-available outcomes database for researchers. West J Emerg Med 2008; 9:6-8.